These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

907 related articles for article (PubMed ID: 25723109)

  • 1. Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement.
    Antonescu CR; Suurmeijer AJ; Zhang L; Sung YS; Jungbluth AA; Travis WD; Al-Ahmadie H; Fletcher CD; Alaggio R
    Am J Surg Pathol; 2015 Jul; 39(7):957-67. PubMed ID: 25723109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uterine Inflammatory Myofibroblastic Tumors Frequently Harbor ALK Fusions With IGFBP5 and THBS1.
    Haimes JD; Stewart CJR; Kudlow BA; Culver BP; Meng B; Koay E; Whitehouse A; Cope N; Lee JC; Ng T; McCluggage WG; Lee CH
    Am J Surg Pathol; 2017 Jun; 41(6):773-780. PubMed ID: 28490045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expanding the Molecular Characterization of Thoracic Inflammatory Myofibroblastic Tumors beyond ALK Gene Rearrangements.
    Chang JC; Zhang L; Drilon AE; Chi P; Alaggio R; Borsu L; Benayed R; Travis WD; Ladanyi M; Antonescu CR
    J Thorac Oncol; 2019 May; 14(5):825-834. PubMed ID: 30550870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spectrum of kinase gene rearrangements in a large series of paediatric inflammatory myofibroblastic tumours.
    Preobrazhenskaya EV; Suleymanova AM; Bizin IV; Zagrebin FA; Romanko AA; Saitova ES; Mulkidzhan RS; Imyanitov EN
    Histopathology; 2023 Jul; 83(1):109-115. PubMed ID: 37071060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours.
    Yamamoto H; Yoshida A; Taguchi K; Kohashi K; Hatanaka Y; Yamashita A; Mori D; Oda Y
    Histopathology; 2016 Jul; 69(1):72-83. PubMed ID: 26647767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare.
    Zhao W; Choi YL; Song JY; Zhu Y; Xu Q; Zhang F; Jiang L; Cheng J; Zheng G; Mao M
    Lung Cancer; 2016 Apr; 94():22-7. PubMed ID: 26973202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
    Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
    J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
    Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
    Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors.
    Hornick JL; Sholl LM; Dal Cin P; Childress MA; Lovly CM
    Mod Pathol; 2015 May; 28(5):732-9. PubMed ID: 25612511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene rearrangements in consecutive series of pediatric inflammatory myofibroblastic tumors.
    Preobrazhenskaya EV; Iyevleva AG; Suleymanova AM; Tiurin VI; Mitiushkina NV; Bizin IV; Ivanstov AO; Gorustovich OA; Shelekhova KV; Kachanov DY; Varfolomeeva SR; Roschin VY; Kazakova AN; Litvinov DV; Shamanskaya TV; Savelov NA; Suspitsin EN; Imyanitov EN
    Pediatr Blood Cancer; 2020 May; 67(5):e28220. PubMed ID: 32064735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel CASC15-ALK and TFG-ROS1 Fusion Observed in Uterine Inflammatory Myofibroblastic Tumor.
    Chang B; Wang Z; Ren M; Yao Q; Zhao L; Zhou X
    Int J Gynecol Pathol; 2023 Sep; 42(5):451-459. PubMed ID: 36730016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abdominal inflammatory myofibroblastic tumour: Clinicopathological and molecular analysis of 20 cases, highlighting potential therapeutic targets.
    Vernemmen AIP; Samarska IV; Speel EM; Riedl RG; Goudkade D; de Bruïne AP; Wouda S; van Marion AM; Verlinden IV; van Lijnschoten I; Friederich P; Winnepenninckx VJL; Zur Hausen A; Sciot RME; van den Hout MFCM
    Histopathology; 2024 Apr; 84(5):794-809. PubMed ID: 38155480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Detection of ALK, ROS1 and RET fusion genes in non-small cell lung cancer patients and its clinicopathologic correlation].
    Zhong S; Zhang H; Bai D; Gao D; Zheng J; Ding Y
    Zhonghua Bing Li Xue Za Zhi; 2015 Sep; 44(9):639-43. PubMed ID: 26705279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions.
    Lovly CM; Gupta A; Lipson D; Otto G; Brennan T; Chung CT; Borinstein SC; Ross JS; Stephens PJ; Miller VA; Coffin CM
    Cancer Discov; 2014 Aug; 4(8):889-95. PubMed ID: 24875859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From genotype to phenotype: Are there imaging characteristics associated with lung adenocarcinomas harboring RET and ROS1 rearrangements?
    Plodkowski AJ; Drilon A; Halpenny DF; O'Driscoll D; Blair D; Litvak AM; Zheng J; Moskowitz CS; Ginsberg MS
    Lung Cancer; 2015 Nov; 90(2):321-5. PubMed ID: 26424208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammatory myofibroblastic tumors of the urinary tract: a clinicopathologic study of 46 cases, including a malignant example inflammatory fibrosarcoma and a subset associated with high-grade urothelial carcinoma.
    Montgomery EA; Shuster DD; Burkart AL; Esteban JM; Sgrignoli A; Elwood L; Vaughn DJ; Griffin CA; Epstein JI
    Am J Surg Pathol; 2006 Dec; 30(12):1502-12. PubMed ID: 17122505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion.
    Furugaki K; Mochizuki M; Kohno M; Shu S; Harada N; Yoshimura Y
    BMC Cancer; 2019 Apr; 19(1):301. PubMed ID: 30943926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive analysis of
    Zhou C; Li M; Guo Z; Li K; Zhai X; Xie Y; Yang X; Wu Y; Xiao W; Xu W
    J Genet; 2020; 99():. PubMed ID: 33168793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma.
    Lee SE; Lee B; Hong M; Song JY; Jung K; Lira ME; Mao M; Han J; Kim J; Choi YL
    Mod Pathol; 2015 Apr; 28(4):468-79. PubMed ID: 25234288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases.
    Yoshida A; Kohno T; Tsuta K; Wakai S; Arai Y; Shimada Y; Asamura H; Furuta K; Shibata T; Tsuda H
    Am J Surg Pathol; 2013 Apr; 37(4):554-62. PubMed ID: 23426121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.